News

Published on 10 Oct 2022 on Zacks via Yahoo Finance

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why


Article preview image

Akouos, Inc. (AKUS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
10 Most Promising Gene Therapy Companies to Watch

In this piece, we will take a look at the ten most promising gene therapy companies to watch. For...

Insider Monkey via Yahoo Finance 14 Nov 2022

Eli Lilly Dividend: Does Eli Lilly Pay Dividends?

Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stoc...

Entrpreneur 27 Oct 2022

The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

For Immediate Release Chicago, IL – October 24, 2022 – Zacks.com announces the list of stocks fea...

Zacks via Yahoo Finance 24 Oct 2022

Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly

Shares of Akouos AKUS skyrocketed 88.16% after the company announced a buyout agreement for appro...

Zacks via Yahoo Finance 20 Oct 2022

Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos

Eli Lilly and Company LLY announced a definitive agreement to acquire Boston-based Akouos, AKUS, ...

Zacks via Yahoo Finance 19 Oct 2022

Why Akouos Stock Is on Fire Today

What happened Shares of small-cap gene therapy company Akouos (NASDAQ: AKUS) popped by as much as...

Motley Fool 18 Oct 2022

Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Session...

Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Sess...

Investing.com 18 Oct 2022

Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss

Eli Lilly and Co. said Tuesday it has entered an agreement to acquire Akouos Inc. a company devel...

MarketWatch 18 Oct 2022

Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why

Akouos, Inc. (AKUS) could be a solid choice for investors given its recent upgrade to a Zacks Ran...

Zacks via Yahoo Finance 10 Oct 2022

FDA Clears Akouos' Gene Therapy Trial For Genetic Form Of Hearing Loss

The FDA has signed off Akouos Inc's (NASDAQ: AKUS) Investigational New Drug application to initia...

Benzinga via Yahoo Finance 13 Sep 2022